Can hormone patches and pills help teens with ovarian failure?

NCT ID NCT06851754

Recruiting now Disease control Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 06, 2026 · Updated 6 times

Summary

This study looks at how hormone replacement therapy (HRT) affects adolescents aged 11-19 with premature ovarian insufficiency (POI), a condition where ovaries stop working before age 40. Participants receive estrogen patches and progesterone pills over 2 years, with regular check-ups to monitor bone health, heart function, and other measures. The goal is to find the best HRT approach for this age group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Estrogen patch and progesterone pill
What this could lead to: If successful, this could establish safe and effective hormone replacement therapy guidelines for adolescents with premature ovarian insufficiency, improving bone density and overall health.
What could go wrong: This is a phase 3 trial, but it is observational in nature and does not compare different treatments. Results may not apply to all patients, and side effects from hormones are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREMATURE OVARIAN INSUFFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

primary ovarian failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PREMATURE OVARIAN INSUFFICIENCY

Contacts and locations

Locations

National Institutes of Health Clinical Center
RECRUITING

Bethesda, Maryland, 20892, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.